Skip to content
value.today
MaxCyte, Inc. logo

MaxCyte, Inc.

Formerly MAXCYTE INC

Total raised
$3 M
2 rounds on record
Latest round
$2 M
Dec 2014
First round on record
Aug 2009
Today
Went public
See the company page

MaxCyte, Inc. is listed today as MaxCyte, Inc.: market value, financials and filings are on its company page.

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of MaxCyte, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Dec 2014$2 MNo. 2Under $2 million

MaxCyte, Inc.: Raise no. 2, Dec 2014

Investors in this round

21 investors had bought by the notice of Dec 16, 2014: 21 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Douglas A. Doerfler · Executive Officer, Director
  • Karen Stark Donato · Executive Officer
  • Madhusudan E. Peshwa · Executive Officer
  • Ronald E. Holtz · Executive Officer
  • Arthur Stark Mandell · Director
  • Dennis Stark Dougherty · Director
  • J. Stark Thompson · Director
  • Sinclair Stark Dunlop · Director
  • Stan Stark Erck · Director
  • Will Stark Brooke · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Up to an additional $500,000 may be sold if authorized by the Company's Board.”
  • On the use of proceeds: “excluding ordinary salary and expenses”

Signed by Ron Holtz, Chief Financial Officer. Source: SEC Form D, newest notice filed Dec 16, 2014. Read the notice at the SEC.

equitySEC
Aug 2009$2 MNo. 1Under $2 million

MaxCyte, Inc.: Raise no. 1, Aug 2009

Investors in this round

15 investors had bought by the notice of Oct 13, 2009: 15 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
no minimum stated
What was sold
equity, debt
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Douglas A. Doerfler · Executive Officer, Director
  • Karen Starke Donato · Executive Officer
  • Madhusadan E. Peshwa · Executive Officer
  • Ronald E. Holtz · Executive Officer
  • Arthur Starke Mandell · Director
  • Chris Starke Hegele · Director
  • David Starke Pierson · Director
  • J. Starke Thompson · Director
  • Sinclair Starke Dunlop · Director
  • Stan Starke Erck · Director
  • Will Starke Brooke · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “excluding ordinary salary and expenses”

Signed by Douglas A. Doerfler, President. Source: SEC Form D and 1 amendment, newest notice filed Oct 13, 2009. Read the notice at the SEC.

equity, debtSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • As the listed company MaxCyte, Inc., its revenue in fiscal 2025 came from these product and service lines: Licenses $12.37 million (37%), Assay and other service revenue $1.97 million (6%).

    Annual report (SEC XBRL) · Dec 2025

  • MaxCyte, Inc. chose not to state its revenue in its newest notice of a funding round (Dec 2014).

    SEC Form D · Dec 2014

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Dec 2014

Products and services#

No products or services of MaxCyte, Inc. are on record.

Investors#

No investor of MaxCyte, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 21 investors.

Largest shareholders today

Institutions holding MaxCyte, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by MaxCyte, Inc.
NameRoleNamed in
Douglas A. DoerflerExecutive officerDec 2014
Karen Stark DonatoExecutive officerDec 2014
Madhusudan E. PeshwaExecutive officerDec 2014
Ronald E. HoltzExecutive officerDec 2014
Karen Starke DonatoExecutive officerOct 2009
Madhusadan E. PeshwaExecutive officerOct 2009
Karen DonatoExecutive officerAug 2009
Madhusadan PeshwaExecutive officerAug 2009
Arthur Stark MandellDirectorDec 2014
Dennis Stark DoughertyDirectorDec 2014
Douglas A. DoerflerDirectorDec 2014
J. Stark ThompsonDirectorDec 2014
Sinclair Stark DunlopDirectorDec 2014
Stan Stark ErckDirectorDec 2014
Will Stark BrookeDirectorDec 2014
Arthur Starke MandellDirectorOct 2009
Chris Starke HegeleDirectorOct 2009
David Starke PiersonDirectorOct 2009
J. Starke ThompsonDirectorOct 2009
Sinclair Starke DunlopDirectorOct 2009
Stan Starke ErckDirectorOct 2009
Will Starke BrookeDirectorOct 2009
Arthur MandellDirectorAug 2009
Chris HegeleDirectorAug 2009
David PiersonDirectorAug 2009
Sinclair DunlopDirectorAug 2009
Stan ErckDirectorAug 2009
Will BrookeDirectorAug 2009

About

Biotech company in Rockville, United States.

Went public since 2021. Its SEC number is that of a company listed on a stock exchange.